阅读说明：本技术 高纯度喹啉衍生物及其生产方法 (High-purity quinoline derivative and process for producing the same ) 是由 中村太树 阿部太一 宫下祐辅 黑田弘文 绫田雄辅 赤尾淳史 于 2015-08-26 设计创作，主要内容包括：本申请涉及高纯度喹啉衍生物及其生产方法。提供了由化学式(IV)所表示的化合物或其盐,其中由化学式(I)所表示的化合物的含量按质量计为350ppm或更少。(The present application relates to high purity quinoline derivatives and methods for their production. There is provided a compound represented by the formula (IV) or a salt thereof, wherein the content of the compound represented by the formula (I) is 350ppm by mass or less.)

1. A composition wherein the content of the methanesulfonate salt of the compound represented by formula (IV) is 98.0% by mass or more, and the content of the compound represented by formula (I) is 183ppm by mass or less

2. A composition, wherein the content of the methanesulfonate salt of the compound represented by formula (IV) is 98.0% by mass or more, and the content of the compound represented by formula (A-1) is 60ppm by mass or less

3. A composition, wherein the content of the methanesulfonate salt of the compound represented by formula (IV) is 98.0% by mass or more, the content of the compound represented by formula (I) is 183ppm by mass or less, and the content of the compound represented by formula (A-1) is 60ppm by mass or less

Field of the invention

The present invention relates to quinoline derivatives and a process for producing the same. More specifically, the present invention relates to a quinoline derivative of high purity and a production process for efficiently obtaining the quinoline derivative.

Related Art

A quinoline derivative represented by the compound (IV):

exhibit excellent antitumor activity (PTL 1).

PTLs 1, 2, 3, 4 and 5 disclose methods for producing these quinoline derivatives. Specifically, in the production method of PTL 1 (as described in example 368), 4-amino-3-chlorophenol hydrochloride is reacted with 4-chloro-7-methoxy-quinoline-6-carboxamide (step a); phenyl chloroformate is reacted with the obtained 4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide, and the resulting phenyl N- {4- (6-carbamoyl-7-methoxy-4-quinolyl) oxy-2-chlorophenyl }) carbamate is isolated (step B); then cyclopropylamine was further reacted with the carbamate (step C) to obtain the objective compound 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide (hereinafter referred to as "compound (IV)"), wherein the total yield of the three steps was 25.5%.

In the production methods described in PTL 2 (reference example 1) and PTL 4 (production example 1), cyclopropylamine was reacted with phenyl N- {4- (6-carbamoyl-7-methoxy-4-quinolyl) oxy-2-chlorophenyl } carbamate to obtain compound (IV) in a yield of 80.2%.

In the production methods described in PTL 2 (reference example 3), PTL 3 (example 4), PTL 4 (production example 3), and PTL 5 (example 1a), the target compound (IV) is obtained from 4-chloro-7-methoxy-quinoline-6-carboxamide in a single step, with a yield of 86.3% in PTLs 2 to 4 and a yield of 91.4% in PTL 5.

Subsequently, the production methods described in PTLs 1 to 5 will be described in detail. The production method described in PTL 1 (example 368, etc.) is as described in the following chemical formula.

Reaction schemes of the production methods in PTL 2 (reference example 1) and PTL 4 (production example 1) are as follows.

The production methods in PTL 2 (reference example 3), PTL 3 (example 4), PTL 4 (production example 3), and PTL 5 (example 1a) have the following reaction schemes.

Reference list

Patent document

[PTL 1]US 2004/0053908

[PTL 2]US 2007/0004773

[PTL 3]US 2007/0037849

[PTL 4]US 2007/0078159

[PTL 5]US 2007/0117842

Summary of The Invention

Technical problem

The inventors have found that in the case of producing a compound represented by chemical formula (IV) or a salt thereof by using the production method described in PTLs 1 to 5, the product contains a compound represented by chemical formula (I), a compound represented by chemical formula (a-1), a compound represented by chemical formula (C-1), and the like as impurities, and it is difficult to remove such impurities by conventional purification methods such as chromatography and crystallization.

Disclosure of Invention

It is therefore an object of the present invention to provide high purity quinoline derivatives accompanied by small amounts of impurities. It is another object of the present invention to provide a production method suitable for mass production to obtain a quinoline derivative with high purity in high yield.

The inventors, in view of the intensive studies on the above-mentioned circumstances, have found a novel method for producing the above-mentioned quinoline derivative, thereby completing the present invention. Accordingly, the present invention provides the following [1] to [27 ]:

[1] a compound represented by the formula (IV) or a salt thereof, wherein the content of the compound represented by the formula (I) is 350ppm by mass or less.

[2] A compound represented by the formula (IV) or a salt thereof, wherein the content of the compound represented by the formula (I) is 183ppm by mass or less.

[3] A compound represented by the formula (IV) or a salt thereof, wherein the content of the compound represented by the formula (A-1) is 60ppm by mass or less.

[4] A compound represented by chemical formula (IV) or a salt thereof, wherein the content of the compound represented by chemical formula (I) is 350ppm by mass or less, and the content of the compound represented by chemical formula (a-1) is 60ppm by mass or less.

[5] A compound represented by chemical formula (IV) or a salt thereof, wherein the content of the compound represented by chemical formula (I) is 183ppm by mass or less, and the content of the compound represented by chemical formula (a-1) is 60ppm by mass or less.

[6] A compound represented by the formula (IV) or a salt thereof, wherein the content of the compound represented by the formula (C-1) is 0.10% by mass or less.

[7] The compound represented by the formula (IV) or a salt thereof according to any one of [1] to [6], wherein the content of the compound represented by the formula (IV) is 98.0% by mass or more.

[8] A composition, wherein the content of the compound represented by the formula (IV) or a salt thereof is 98.0% by mass or more, and the content of the compound represented by the formula (I) or a salt thereof is 350ppm by mass or less.

[9] A composition, wherein the content of the compound represented by the formula (IV) or a salt thereof is 98.0% by mass or more, and the content of the compound represented by the formula (I) or a salt thereof is 183ppm by mass or less.

[10] A composition, wherein the content of the compound represented by the chemical formula (IV) or a salt thereof is 98.0% by mass or more, and the content of the compound represented by the chemical formula (a-1) or a salt thereof is 60ppm by mass or less.

[11] A composition, wherein the content of the compound represented by the formula (IV) or a salt thereof is 98.0% by mass or more, the content of the compound represented by the formula (I) or a salt thereof is 350ppm by mass or less, and the content of the compound represented by the formula (a-1) or a salt thereof is 60ppm by mass or less.

[12] A composition, wherein the content of the compound represented by the formula (IV) or a salt thereof is 98.0% by mass or more, the content of the compound represented by the formula (I) or a salt thereof is 183ppm by mass or less, and the content of the compound represented by the formula (a-1) or a salt thereof is 60ppm by mass or less.

[13] A composition, wherein the content of the compound represented by the chemical formula (IV) or a salt thereof is 98.0% by mass or more, and the content of the compound represented by the chemical formula (C-1) or a salt thereof is 0.10% by mass or less.

[14] A medicament comprising the compound according to any one of [1] to [7] or a salt thereof as an active ingredient.

[15] A medicament comprising the composition according to any one of [8] to [13] as an active ingredient.

[16] A pharmaceutical composition using the compound according to any one of [1] to [7] or a salt thereof as an active ingredient, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[17] A pharmaceutical composition comprising the composition according to any one of [8] to [13] as an active ingredient, wherein the pharmaceutical composition further comprises a pharmaceutically acceptable carrier.

[18] An oral solid formulation comprising the compound according to [4] or a salt thereof as an active ingredient, wherein the oral solid formulation further comprises a pharmaceutically acceptable carrier, and the content of the compound represented by the formula (I) is 0.06% by mass or less.

[19] An oral solid formulation comprising the composition according to [8] or [11] as an active ingredient, wherein the oral solid formulation further comprises a pharmaceutically acceptable carrier, and the content of the compound represented by the formula (I) is 0.06% by mass or less.

[20] An oral solid formulation comprising the compound according to [5] or a salt thereof as an active ingredient, wherein the oral solid formulation further comprises a pharmaceutically acceptable carrier, and the content of the compound represented by the formula (I) is 0.040% by mass or less.

[21] An oral solid formulation comprising the composition according to [9] or [12] as an active ingredient, wherein the oral solid formulation further comprises a pharmaceutically acceptable carrier, and the content of the compound represented by the formula (I) is 0.040% by mass or less.

[22] A process for producing a compound represented by the formula (IV)

Or a salt thereof, the method comprising:

step B of allowing the compound represented by the formula (I)

Or a salt thereof with a compound represented by the formula (II-A) or the formula (II-B) in the presence of a base

Wherein R is¹Is C_1-6Alkyl radical, C_2-6Alkenyl radical, C_6-10Aryl radicals, or C_7-11An aralkyl group, wherein the C_1-6Alkyl radical or the C_2-6The alkenyl group may contain one to three substituents which may be the same or different and are selected from the group consisting of halogen atoms and methoxy groups, and wherein C_6-10Aryl radical or the C_7-11The aralkyl group may contain one to three substituents which may be the same or different and are selected from the group consisting of: halogen atoms, methyl groups, methoxy groups and nitro groups; and X is a halogen atom,

thereby obtaining a compound represented by the formula (III)

Wherein R is¹Is the same group as described above, and

step C, after allowing the compound represented by the formula (III) obtained in the step B to react with cyclopropylamine without separation, precipitating and isolating the compound represented by the formula (IV) by introducing an aqueous organic solvent into the reaction solution

Or a salt thereof.

[23] A process for producing a compound represented by the formula (IV)

Or a salt thereof, the method comprising:

step A of allowing a compound represented by the formula (A-1) in the presence of a base

With a compound represented by the formula (A-2)

Or a salt thereof, precipitating and isolating the compound represented by formula (I) from the reaction solution by introducing an aqueous organic solvent into the reaction solution

Or a salt thereof,

step B of allowing the compound represented by the formula (I) obtained in step A to react in the presence of a base

Or a salt thereof with a compound represented by the formula (II-A) or the formula (II-B)

Wherein R is¹Is C_1-6Alkyl radical, C_2-6Alkenyl radical, C_6-10Aryl radicals, or C_7-11An aralkyl group, wherein the C_1-6Alkyl radical or the C_2-6The alkenyl group may contain one to three substituents which may be the same or different and are selected from the group consisting of halogen atoms and methoxy groups, and wherein C_6-10Aryl radical or the C_7-11The aralkyl group may contain one to three substituents which may be the same or different and are selected from the group consisting of: halogen atoms, methyl groups, methoxy groups and nitro groups; and X is a halogen atom,

thereby obtaining a compound represented by the formula (III)

Wherein R is¹Is the same group as described above, and

step C, after allowing the compound represented by the formula (III) obtained in the step B to react with cyclopropylamine without separation, precipitating and isolating the compound represented by the formula (IV) by introducing an aqueous organic solvent into the reaction solution

Or a salt thereof.

[24] The method according to [22] or [23], further comprising a step D of converting the compound represented by the formula (IV) obtained in the step C into a salt of the compound represented by the formula (IV).

[25] The process according to [24], wherein the salt obtained in the step D is a methanesulfonate salt.

[26] The method according to any one of [22] to [25], wherein the step B is a step of: in this step, a compound represented by the formula (I) is allowed to stand

Or a salt thereof with a compound represented by the formula (II-A) in the presence of a base

Wherein R is¹Is C_6-10Aryl radical, C_6-10The aryl group may contain one to three substituents which may be the same or different and are selected from the group consisting of: halogen atoms, methyl groups, methoxy groups and nitro groups; and X is a halogen atom,

thereby obtaining a compound represented by the formula (III)

Wherein R is¹Are the same groups as described above.

[27] The method according to any one of [22] to [26], wherein the compound represented by the formula (II-A) is phenyl chloroformate.

Advantageous effects of the invention

According to the present invention, the compound (IV) can be provided in high yield and high purity.

Description of the embodiments

Symbols and terms used throughout the present specification will now be explained.

In the present specification, "compound" includes various anhydrates, hydrates, and solvates. Also, in the present specification, "compound (I)" and the like each mean the same compound as "compound represented by formula (I)" and the like.

In the present specification, "compound or a salt thereof" means a compound or a salt thereof that includes 90% by mass or more of the compound and may contain a starting material or a formed by-product as an impurity. For example, "the compound represented by the formula (IV) or a salt thereof" contains 90% by mass or more of the compound (IV) or a salt thereof, and may contain starting materials such as the compound (I), the compound (a-1), and by-products such as the compound (C-1) which may be formed in each production step. Therefore, the "compound or a salt thereof" which may contain by-products as impurities and the like in the present specification has a concept of "composition". In terms of expressing the content of impurities (here, such as the compound (I), the compound (A-1) and the compound (C-1)), the content is based on the total mass of the compound (IV) or a salt thereof.

In the present specification, "pharmaceutical composition" refers to a composition comprising a compound having a pharmacological effect or a salt thereof, and a pharmaceutically acceptable carrier. An example of the compound having a pharmacological effect or a salt thereof is compound (IV) or a salt thereof. Alternatively, with respect to pharmaceutical compositions, "formulations" means those formulations that have been subjected to processing (e.g., sterilization and tableting) to a state that can be administered as needed to a subject in need thereof. Alternatively, "drug" is used to treat or prevent a disease and includes any drug in an arbitrary form.

And, as used herein, the term "C_1-6An alkyl group "means a monovalent group obtained by removing any hydrogen from a C1-6 aliphatic saturated hydrocarbon, and it is a C1-6 straight or branched chain substituent. C_1-6Examples of alkyl groups include methyl, ethyl, 1-propyl, 2-methyl-1-propyl, 2-methyl-2-propyl, 1-butyl, 2-butyl, 1-pentyl, 2-pentyl, 3-pentyl, 1-hexyl, 2-hexylAnd 3-hexyl groups, preferably methyl, ethyl and 1-propyl groups.

The term "C" as used herein_1-6An alkenyl group "means a monovalent group obtained by removing any hydrogen from a C1-6 aliphatic hydrocarbon having an unsaturated bond, and it is a C1-6 straight or branched chain substituent. C_1-6Examples of alkenyl groups include 2-propenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 2-hexenyl, 3-hexenyl and 4-hexenyl groups, with a 2-propenyl group being preferred.

The term "C" as used herein_6-10Aryl group "means a C6-10 aromatic cyclic hydrocarbon group. C_6-10Examples of aryl groups include phenyl, 1-naphthyl and 2-naphthyl groups, with phenyl groups being preferred.

The term "C" as used herein_7-11An aralkyl group "means a C7-11 aralkyl group. C_7-11Examples of aralkyl groups include benzyl and naphthylmethyl groups, with benzyl groups being preferred.

The term "halogen atom" as used herein refers to a fluorine, chlorine, bromine or iodine atom, and preferably a chlorine atom.

The term "base" as used herein may refer to inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium tert-butoxide, sodium bicarbonate, potassium bicarbonate, or cesium carbonate; metal organic reagents such as butyl lithium, methyl lithium, lithium bis-trimethylsilylamide, sodium bis-trimethylsilylamide or potassium bis-trimethylsilylamide; hydrides such as lithium hydride, sodium cyanide or potassium hydride; heterocyclic compounds such as imidazole, pyridine, lutidine, collidine or 4-dimethylaminopyridine; or an organic amine such as triethylamine, N-diisopropylethylamine or diazabicycloundecene.

The compound (I) or a salt thereof may be an anhydride, a hydrate or a solvate, and an example of the solvate is a dimethylsulfoxide solvate.

There is no particular limitation on the salt of compound (I), and examples of the salt of compound (I) include inorganic acid salts, organic acid salts, and acidic amino acid salts.

There is no particular limitation on the salt of compound (IV), and examples of the salt of compound (IV) include inorganic acid salts, organic acid salts, and acidic amino acid salts.

Preferred examples of the inorganic acid salt include hydrochloride, hydrobromide, sulfate, nitrate and phosphate.

Preferred examples of the salts of organic acids include acetate, succinate, fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, ethanesulfonate, and p-toluenesulfonate, preferably methanesulfonate.

Preferred examples of the acidic amino acid salt include aspartic acid salt and glutamic acid salt.

There are no specific limitations on the salt of the compound represented by the formula (a-2), and examples include inorganic acid salts such as hydrochloric acid and hydrobromic acid salts.

The production process of the present invention will now be explained in more detail.

The production method 1: process for producing Compound (I) or a salt thereof (step A)

Step A is a step in which compound (A-2) or a salt thereof is reacted with compound (A-1) to obtain compound (I) or a salt thereof.

The reaction solvent is not particularly limited as long as it dissolves the starting material and does not interfere with the reaction, and for example, it may be dimethyl sulfoxide, N-dimethylformamide, N-dimethylacetamide, 1, 3-dimethyl-2-imidazolidinone, or the like, preferably dimethyl sulfoxide.

The compound (A-2) or a salt thereof may be used in an equivalent of 1.0 to 2.0 relative to the number of moles of the compound (A-1).

The base is not particularly limited, and for example, it may be a base such as cesium carbonate, potassium tert-butoxide or potassium hydroxide, preferably potassium hydroxide. The base may be used in an equivalent of 1.5 to 2.0 relative to the molar amount of the compound (a-2) or a salt thereof used in the reaction.

The reaction time also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably 5 to 100 hours, and more preferably 10 to 30 hours.

The reaction temperature also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably from room temperature to the reflux temperature of the solvent, more preferably from 60 ℃ to 80 ℃ and even more preferably from 65 ℃ to 75 ℃.

When the reaction is completed, an aqueous organic solvent may be introduced into the reaction mixture to precipitate and isolate compound (I) or a salt thereof. The amount of the aqueous organic solvent to be introduced may be 10 to 20-fold (v/w) by volume relative to the mass of the compound (A-1). Also, the aqueous organic solvent used may be, for example, water/acetone (volume ratio: 50/50 to 80/20).

By changing the drying conditions, i.e., conditions such as temperature and degree of reduced pressure, compound (I) or a salt thereof can be obtained as an anhydrate, a hydrate or a solvate.

The production method 2 comprises the following steps: process for producing Compound (IV) or a salt thereof (Steps B and C)

The method comprises a step in which compound (I) or a salt thereof obtained in the above production method 1 is reacted with compound (II) to obtain compound (III) (step B); and a step in which compound (III) as an activated form of compound (I) is reacted without separation with cyclopropylamine to obtain compound (IV) or a salt thereof (step C). The term "compound (II)" is a general term referring to an agent for converting compound (I) into its activated form of compound (III), and it may be compound (II-A), compound (II-B) or another activating agent.

The reaction solvent is not particularly limited as long as it does not inhibit the reaction, and for example, N-dimethylformamide, 1-methyl-2-pyrrolidone, 1, 3-dimethyl-2-imidazolidinone, dimethylsulfoxide, tetrahydrofuran, acetonitrile, or the like can be used, with N, N-dimethylformamide being preferred.

In the compound represented by the formula (II-A) or the formula (II-B):

R¹is C_1-6Alkyl radical, C_1-6Alkenyl radical, C_6-10Aryl or C_7-11An aralkyl group, wherein the C_1-6Alkyl radical or the C_1-6The alkenyl group optionally contains one to three substituents which are the same or different and selected from the group consisting of halogen atoms and methoxy groups; and the C_6-10Aryl radicals or C_7-11The aralkyl group optionally contains one to three identical or different substituents selected from the group consisting of: halogen atoms, methyl, methoxy and nitro groups; and X is a halogen atom. And, two R in the formula (II-B)¹The groups may together with alkylene groups, such as ethylene groups, form cyclic carbonates.

Examples of the compound (II-A) include methyl chloroformate, ethyl chloroformate, isopropyl chloroformate, ethyl 2-methoxychloroformate, chloroethyl 1-chloroformate, isobutyl chloroformate, 2,2, 2-trichloroethyl chloroformate, propyl chloroformate, chloroethyl 2-chloroformate, phenyl chloroformate, naphthyl 2-chloroformate, benzyl chloroformate, chlorophenyl 4-chloroformate and nitrophenyl 4-chloroformate, and examples of the compound (II-B) include dimethyl carbonate, diethyl carbonate, triphosgene, bis (2-chloroethyl) carbonate, diallyl carbonate, diphenyl carbonate, dibenzyl carbonate and ethylene carbonate. As other activators, instead of the compound (II-A) or the compound (II-B), dicarboxylic acid esters such as di-tert-butyl dicarbonate or 1,1' -carbonyldiimidazole may be used. The compound (II) is preferably phenyl chloroformate.

Compound (II) may be used in an equivalent of 1.0 to 3.0 relative to the number of moles of compound (I).

There is no particular limitation on the base, and for example, pyridine, collidine, lutidine, potassium hydroxide, potassium carbonate, sodium hydrogencarbonate, triethylamine, N-diisopropylethylamine or the like, preferably pyridine, can be used.

The base may be used in an equivalent of 1.0 to 3.0 relative to the number of moles of the compound (I).

Water may be added to the reaction solvent in an amount of preferably 0.5 to 2.0 equivalents, more preferably 1.0 to 1.5 equivalents, and particularly preferably 1.0 equivalent, relative to the number of moles of compound (I).

The reaction time of step B also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably from 15 minutes to 24 hours.

The reaction temperature of step B also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably from-50 ℃ to room temperature, and more preferably from-30 ℃ to 0 ℃.

The compound (III) which is not separated from the reaction mixture in step B is supplied to step C. Cyclopropylamine is used in an equivalent amount of 1.0 to 7.2 relative to the moles of compound (II).

The reaction in step C will be carried out with cyclopropylamine alone, but the reaction can also be carried out in the presence of both cyclopropylamine and another base. There is no particular limitation on the other base, and the base may be a tertiary amine such as triethylamine, N-diisopropylethylamine or tributylamine, or a heterocyclic compound such as pyridine. Here, cyclopropylamine may be used in 1.0 to 5.0 equivalents relative to the number of moles of the compound (II), and other base may be used in 1.0 to 5.0 equivalents relative to the number of moles of the compound (II).

The reaction time of step C also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably from 30 minutes to 90 hours.

The reaction temperature of step C also generally varies depending on the starting materials, solvents and other reagents used in the reaction, but is preferably from-20 ℃ to 40 ℃, and more preferably from 0 ℃ to 20 ℃.

After completion of the reaction, compound (IV) or a salt thereof may be precipitated and isolated by introducing an aqueous organic solvent into the reaction solution. The amount of the aqueous organic solvent to be introduced may be set to a volume 10-to 20-fold (v/w) with respect to the mass of the compound (I). Examples of organic solvents that can be used as the aqueous organic solvent include, but are not particularly limited to, acetone, isopropyl acetate, ethanol, 1-propanol, 2-propanol, and N, N-dimethylformamide. Examples of the aqueous organic solvent are preferably water/acetone (in a volume ratio of 3/100 to 1/20), water/isopropyl acetate (in a volume ratio of 1/20), and water/ethanol (in a volume ratio of 1/1), and more preferably water/acetone (in a volume ratio of 1/20). It should be noted that seed crystals may be added as needed with the introduction of the aqueous organic solvent. Alternatively, compound (IV) or a salt thereof may also be precipitated and isolated by introducing water into the reaction solution after completion of the reaction.

The obtained crystals may be washed with a solvent such as water or acetone to obtain crystals of compound (IV) (crude product). For purification, the crystals (crude product) may then be crystallized using a solvent such as 1, 3-dimethyl-2-imidazolidinone, N-dimethylformamide, dimethyl sulfoxide, 2-propanol or isopropyl acetate.

Step D is a step in which compound (IV) obtained in step C is converted into a salt. Preferably the salt of compound (IV) is the mesylate salt.

Crystals of a salt such as 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide mesylate can be produced by the method described in PTL 4.

More specifically, in the case of producing 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide methanesulfonate, for example, can be prepared by dissolving 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide after mixing 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide, acetic acid, and methanesulfonic acid, 1-propanol was added as a poor solvent and the solution was gradually cooled to produce a methanesulfonate salt (crystal (C) described in patent document 4). It should be noted that preferably the methanesulfonate crystals (C) are added as seed crystals together with a poor solvent and isopropyl acetate is added to promote precipitation. As the seed crystal, a methanesulfonate crystal (C) produced according to the method described in patent document 4 or according to the method disclosed in the present specification may be used.

The amount of acetic acid added is not particularly limited, but an amount of preferably 5 to 10-fold and more preferably 6 to 8-fold may be used relative to the mass of the compound (IV).

As the amount of methanesulfonic acid added, 1.00 to 1.50 equivalents, preferably 1.05 to 1.30 equivalents, more preferably 1.05 to 1.22 equivalents, and particularly preferably 1.20 equivalents may be used relative to the number of moles of the compound (IV).

Methanesulfonic acid may be mixed with compound (IV) once or in portions; and preferably another 0.10 to 0.20 equivalents, and more preferably another 0.15 equivalents are used after preferably 1.00 to 1.10 equivalents and more preferably 1.05 equivalents are used with respect to the number of moles of the compound (IV).

In the case of the production of salts of 4- [ 3-chloro-4- (cyclopropylaminocarbonyl)) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide and other acids, the desired acid can be used instead of methanesulfonic acid. The amount of acid added should be adjusted by referring to the amount of methanesulfonic acid added, as appropriate.

The reaction temperature in step D also generally varies depending on the starting materials, solvents and other reagents used in the reaction, and is preferably 20 ℃ to 40 ℃, and more preferably 25 ℃ to 35 ℃.

As the poor solvent, methanol, ethanol, 1-propanol, 2-propanol and the like can be used, and 1-propanol is preferred.

The amount of the poor solvent is not particularly limited, but an amount of 2 to 15-fold and more preferably an amount of 8 to 10-fold is preferably used with respect to the mass of the compound (IV).

In the case of adding isopropyl acetate, the amount is not particularly limited, and an amount of 2 to 10-fold and more preferably 5-fold is preferably used with respect to the mass of compound (IV).

The cooling temperature is not particularly limited, but is preferably 15 ℃ to 25 ℃.

The crystals obtained by filtration were stirred in ethanol. The amount of ethanol to be used is not particularly limited, but an amount of 5 to 10-fold and more preferably an amount of 7.5-fold is preferably used with respect to the mass of the compound (IV).

The obtained crystals are preferably stirred in ethanol at 20 ℃ to 60 ℃ for 2 to 5 hours, and more preferably for 3 hours.

According to the above production method, the contents of the compound (A-1), the compound (I), and the compound (C-1) in the methanesulfonic acid salt of the compound (IV) can be set to 60ppm by mass or less, 350ppm by mass or less, and 0.10% by mass or less, respectively.

Specifically, the content of compound (I) in the methanesulfonate salt of compound (IV) may be reduced to 183ppm by mass or less by using cyclopropylamine in excess in step C, or by performing recrystallization of compound (IV) before the synthesis of the methanesulfonate salt of compound (IV).

Compound (A-1) is the starting material for step A, but its solubility in organic solvents is very low. Therefore, it is difficult to remove the compound (A-1) from the compound (IV) or a salt thereof by recrystallization. However, according to the production method according to the present invention, the content of compound (a-1) in compound (IV) or a salt thereof can be reduced by a synthetic route through a plurality of stages, from step a through step B to step C. In particular, according to the consideration of the present inventors, since the compound (A-1) is likely to show genotoxicity, it is important to reduce the content of the compound (A-1) in the compound (IV) or a salt thereof.

It is preferable that the content of compound (A-1) in compound (IV) or a salt thereof is 60ppm by mass or less based on a toxicological concern threshold (TTC) specified in "genotoxic impurity limit guideline" issued by the European drug administration.

[ expression 1]

Compound (I) is the starting material for step B, and unreacted compound (I) remains as an impurity in compound (III) or is formed by decomposition of compound (III), or compound (IV) or a salt thereof in step B. Specifically, when the methanesulfonic acid salt in the compound (IV) is heated after being dissolved in a solvent, the compound (I) is formed as a decomposition product of the compound (IV) and the like. According to the production method according to the present invention, the content of compound (I) in compound (IV) or a salt thereof can be further reduced by using cyclopropylamine in an excess amount in step C, or by dividing a minimum necessary amount of methanesulfonic acid and mixing it with compound (IV) when synthesizing a salt of compound (IV) in step D. In addition, the content of compound (I) in the salt of compound (IV) may be further reduced by performing recrystallization of compound (IV) before synthesizing the salt of compound (IV), thereby reducing the content of compound (I) in the salt of compound (IV). Specifically, compound (I) is a Chemical substance which is published on "professional safety website of the Ministry of Health, labor and Welfare of Japan" Chemical substances having recognized strong mutagenicity "(on Chemical substances on high strength chemistry waters recognited)" (2012, 3/27 th, Japan department of Health, labor and Welfare, bulletin No. 166), and it is important to reduce the content of compound (I) in compound (IV).

Since it is difficult to constantly control the content of compound (I) in compound (IV) or a salt thereof to be equal to or lower than TTC, it is preferable to make the content at a reasonably feasible minimum (ALARP) level, i.e., 350ppm by mass or less based on the measured average values of production lots 1 to 8 and the upper limit of the confidence interval. According to one example of the production method of the present invention, as shown in table 1, the content of the compound (I) contained in the methanesulfonate salt of the compound (IV) may be reduced to 350ppm by mass or less. Specifically, the content of compound (I) can be reduced to 350ppm by mass or less by using potassium hydroxide as a base in step a in 5 to 8 lots suitably combined, additionally isolating compound (I) as its anhydrous crystal after step a in 6 to 8 lots and adding water to the reaction solution in step B, using cyclopropylamine in excess in step C and carrying out recrystallization of compound (IV) in 5 to 8 lots before step D, and the like.

[ Table 1]

Batch of	Compound (I)a
		1	280
2	180
		3	171
4	173
		5	61
6	120
		7	118
8	114
		Mean value of	152.1
Standard deviation of	65.3
		Mean + upper limit of confidence intervalb	348
Acceptance criteria	≤350

Unit: ppm by mass

^aThe limit of quantitation (lower limit) was 7ppm by mass.

^bUpper confidence interval limit is three times the standard deviation of the batch analysis data

Since it is difficult to constantly control the content of the compound (I) in the compound (IV) or a salt thereof to be equal to or lower than TTC, it is preferable to make the content at a reasonably feasible minimum (ALARP) level, i.e., 183ppm by mass or less based on the measured data mean value of 5 to 10 of the production lot and the upper limit of the confidence interval. Specifically, the content of compound (I) contained in the methanesulfonate salt of compound (IV) can be further reduced to 183ppm by mass or less as shown in table 2 by appropriately combining use of potassium hydroxide as a base in step a of 5 to 10 lots, additional isolation of compound (I) as its anhydride crystals after step a in 6 to 10 lots and addition of water to the reaction solution in step B, use of an excess of cyclopropylamine in step C and recrystallization of compound (IV) before step D in 5 to 10 lots, and discrimination of methanesulfonic acid and mixing thereof with compound (IV) in step D of 9 to 10 lots, and the like.

[ Table 2]

Batch of	Compound (I)a
		5	61
6	120
		7	118
8	114
		9	93
10	52
		Mean value of	93.0
Standard deviation of	30
		Mean + upper limit of confidence intervalb	183
Acceptance criteria	≤183

Unit: ppm by mass

^aThe limit of quantitation (lower limit) is 7p by masspm。

^bUpper confidence interval limit is three times the standard deviation of the batch analysis data

Compound (C-1) is a by-product formed mainly in step B. In step B, the formation of compound (C-1) can be more effectively inhibited by further adding one equivalent of water to the reaction solution. It should be noted that in the case where compound (I) monohydrate is used as a starting material, the formation of compound (C-1) can be inhibited without adding an equivalent of water.

The content of compound (C-1) in compound (IV) or a salt thereof is preferably 0.10% by mass or less in accordance with the guidelines of ICH Q3A.

In view of the batch analysis data, stability test and analysis variability, it is preferable that the purity of compound (IV) or a salt thereof is 98.0% by mass or more.

In the case of formulating compound (IV) or a salt thereof, a pharmaceutical composition comprising compound (IV) or a salt thereof and an appropriate additive (as a pharmaceutically acceptable carrier) is generally used. However, the above description is not intended to deny the formulation by using only compound (IV) or a salt thereof.

As the above additives, excipients, binders, lubricants, disintegrants and the like which can be used in the pharmaceutical field can be generally used. As the above additives, they may be used in combination as appropriate.

Examples of the above excipients include lactose, sucrose, glucose, mannitol, pregelatinized starch, and crystalline cellulose.

Examples of the above-mentioned binder include methyl cellulose, hydroxypropyl methyl cellulose, and hydroxypropyl cellulose.

Examples of such lubricants include magnesium stearate, talc, polyethylene glycol, and silica sol.

Examples of the above-mentioned disintegrating agent include crystalline cellulose, agar, gelatin, calcium carbonate, and sodium hydrogencarbonate.

In addition, examples of the above formulations include oral solid formulations such as tablets, powders, granules, capsules, syrups, troches, and inhalants. The formulation obtained by formulating compound (IV) or a salt thereof, or a pharmaceutical composition comprising the same, is generally contained in a suitable primary package (container or packet) and processed as a medicament. As the primary package, a package of a shape suitable for each formulation application may be used.

The above oral solid formulation is formulated by combining the above additives as appropriate. It should be noted that a coating may be applied to the surface of the oral solid formulation as desired.

The oral solid formulation may be produced in accordance with, for example, the specifications of WO 2006/030826 or WO 2011/021597. In the case of preparing a 5% aqueous solvent (W/W) for stabilizing compound (IV) or a salt thereof, it is preferable to use a compound having a pH of 8 or higher as a pharmaceutically acceptable carrier. Alternatively, in order to stabilize compound (IV) or a salt thereof, a carbonate of an alkaline earth metal may be used as a pharmaceutically acceptable carrier.

Primary packaging for oral solid formulations is, for example, a glass or plastic bottle or can. Plastic herein refers to polymers such as High Density Polyethylene (HDPE). In addition, in the case where the oral solid formulation is contained in a bottle, a desiccant such as silica gel may be packaged together with the above formulation.

An example of the above-mentioned drug is an HDPE bottle in which a tablet or capsule containing compound (IV) or a salt thereof and silica gel are sealed. Specifically, an example is an HDPE bottle in which about 30 capsules containing compound (IV) or a salt thereof are sealed with about 2g of silica gel.

Another example of primary packaging for oral solid formulations is blister packaging. An example of a blister pack is a blister pack (PTP). The PTP is constructed of a molding material, a cover material, and the like.

Examples of the components of the above molding materials include metals such as aluminum, and plastics such as polyvinyl chloride (PVC), polyvinylidene chloride (PVDC), cyclic polyolefins, polyamides, and polypropylene (PP). The molding material may be a single component monolayer material, or may be a multi-component laminate, such as an aluminum composite film. The lid material is composed of a supporting material such as aluminum or plastic, and a heat sealing agent and the like as required.

Examples of the PTP are, for example, PTP composed of a molding material of an aluminum composite film and an aluminum lid material, or PTP composed of a molding material made of plastic and an aluminum lid material. For such PTP, secondary packaging (pillow packaging) can be applied using polyethylene or aluminum as required. Additionally, a desiccant may be used with the PTP in a pillow pack.

One example of such a medicament is a PTP in which a tablet or capsule containing compound (IV) or a salt thereof is accommodated, wherein the PTP is composed of an aluminum composite film and aluminum.

The vial or PTP may be contained in a box or the like, as a final package form, along with package instructions for the medication.

In an oral solid formulation comprising compound (IV) or a salt thereof, compound (I) increases by at most 0.02% during storage in an accelerated test, as shown in the examples described below. In other words, as shown in table 1, when an oral solid formulation containing compound (IV) or a salt thereof, in which the content of compound (I) is 350ppm by mass or less, is stored under the storage conditions of the accelerated test described below or is at room temperature for three years during storage, the content of compound (I) in the oral solid formulation is maintained at 0.06% by mass or less.

Accordingly, one aspect of the present invention is an oral solid formulation comprising compound (IV) or a salt thereof and a pharmaceutically acceptable carrier, and wherein the content of compound (I) is 0.06% by mass or less.

Alternatively, as shown in table 2, when an oral solid formulation containing compound (IV) or a salt thereof, in which the content of compound (I) is 183ppm by mass or less, is stored under the storage conditions of the accelerated test described below or at room temperature for three years during storage, the content of compound (I) in the oral solid formulation is maintained at 0.04% by mass or less or at 0.040% by mass or less.

Accordingly, one aspect of the present invention is an oral solid formulation comprising compound (IV) or a salt thereof and a pharmaceutically acceptable carrier, and wherein the content of compound (I) is 0.04% by mass or less or 0.040% by mass or less.

In the case of using the compound (IV) or a salt thereof for the production of a medicament, the amount to be used varies depending on the symptoms, age and administration form, but is generally used for an adult in which 100 μ g to 10g is administered once a day, or is used in portions several times a day.

Examples of the invention

The invention will now be further explained by way of examples, it being understood that the invention is not limited to these examples.

Example 1:4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide

A mixture of 43.5kg of 4-amino-3-chlorophenol hydrochloride, 53.8kg of 48.5 w/w% aqueous potassium hydroxide, 44.0kg of 4-chloro-7-methoxy-quinoline-6-carboxamide and 396L of dimethyl sulfoxide was stirred at 70 ℃ under nitrogen for 20 hours. After aqueous acetone (acetone: 220L, purified water: 440L) was added to the reaction mixture at 55 deg.C, the mixture was cooled to 8 deg.C, and the precipitated precipitate was filtered. The precipitate was washed with an aqueous acetone solution, and the obtained solid was dried under reduced pressure to obtain 59.3kg of 4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide (yield: 93%).

Example 2:4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy]-7-methoxy-6-quinoline-carboxamide

To a mixture of 26.0kg of 4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide, 13.2kg of pyridine, 1.36kg of water and 196.0L of N, N-dimethylformamide was added 26.6kg of phenyl chloroformate under nitrogen atmosphere at-20 ℃ and the mixture was stirred for 3 hours. Then, at 8 ℃, 19.4kg of cyclopropylamine was further added, and the mixture was stirred for 15 hours. After adding 13.0L of water and 261.0L of acetone to the reaction mixture, the precipitated precipitate was filtered. The precipitate was washed with acetone, and the obtained solid was dried under reduced pressure to obtain 28.7kg of a crude product of the title compound (89% yield). Crystallization from 359.6L of 1, 3-dimethyl-2-imidazolidinone and 575.0L of 2-propanol gave 25.7kg of Compound (IV) (90% yield).

In examples 1 and 2, as for the starting material of compound (I), the total yield of the crude product of compound (IV) obtained by these two steps is 83%, and this is a high yield (three steps, 25.5%) compared to the yield in the production method of PTL 1. Also, the crystallization of compound (IV) allows compound (IV) to be obtained in a higher purity in a yield of 90%.

Example 3:4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy]-7-methoxy-6-quinoline-carboxamide methyl ester Sulfonate salt

4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide (23.0kg) was dissolved in a mixed solution of methanesulfonic acid (5.44kg) and acetic acid (150L) at 20 ℃ to 35 ℃. Further methanesulfonic acid (777g) was added, the solution was filtered at 35 ℃ or lower, and the filter paper was washed with acetic acid (11.5L). To the filtrate were added 1-propanol (46.0L) and seed crystals (230g) at 25 ℃ to 45 ℃ and further dropwise added 1-propanol (161L) and isopropyl acetate (115L) at 25 ℃ to 45 ℃. The mixed solution was cooled to 15 ℃ to 25 ℃, and then the deposited crystals were filtered and washed with a mixed solution of 1-propanol and isopropyl acetate (1-propanol concentration: 33 v/v%). Ethanol (173L) was added to the resulting wet crystals and stirred at 20 to 60 ℃ for 3 hours. After the crystals were collected by filtration and washed with ethanol, the crystals were dried under reduced pressure at a temperature of 80 ℃ or less to obtain 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide methanesulfonate (27.5kg, yield: 94%).

Example 4:4- (4-amino-3-chlorophenoxy) -7-methoxyquinoline-6-carboxamide monohydrate

A mixture of 4-amino-3-chlorophenol hydrochloride (593.4g), 48.7 w/w% aqueous potassium hydroxide (730.6g), 4-chloro-7-methoxy-quinoline-6-carboxamide (600.0g), and dimethyl sulfoxide (5.4L) was stirred at 70 ℃ for 21 hours under a nitrogen atmosphere. After 3.0g of seed crystals were introduced into the reaction solution, aqueous acetone (acetone: 3L, purified water: 6L) was added at 55 ℃ and cooled to 8 ℃ and the precipitated precipitate was filtered. The precipitate was washed with aqueous acetone, and a solid was obtained at 60 ℃ under reduced pressure using a rotary evaporator, to obtain 4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide monohydrate (862.7g, yield: 94%).

Example 5: 4- [ 3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy ] -7-methoxy-6-quinoline-carboxamide

Phenyl chloroformate (865.6g) was added to a mixture of 4- (4-amino-3-chlorophenoxy) -7-methoxy-quinoline-6-carboxamide monohydrate (800g), pyridine (524.8g), and N, N-dimethylformamide (8L) under a nitrogen atmosphere at-20 ℃ and stirred for one hour. Additionally, cyclopropylamine (757.6g) was added and stirred at 8 ℃ for 18 h. To the reaction solution was added water (8L), and the precipitated precipitate was filtered. The deposit was washed with aqueous N, N-dimethylformamide and ethanone, and the obtained solid was dried under reduced pressure to obtain a crude product of the title compound (910g, yield: 96%). Five hundred grams of the crude product was crystallized from 1, 3-dimethyl-2-imidazolidinone (6250mL) and 2-propanol (10L) to obtain compound (IV) (450g, yield: 90%).

Purity test 1

For the precipitated crude product of the compound (IV) obtained in example 2, the compound (IV) obtained according to the production method described in patent document 1, and the precipitated crude products of the compound (IV) obtained according to the production methods described in patent documents 2, 3, 4, and 5, their purities were analyzed by liquid chromatography and compared each other. As shown in table 3, the content of the compound (IV) produced in example 2 was higher than that of the compound (IV) obtained according to the production methods described in patent documents 1 to 5, and the total content of impurities was lower.

The results are shown in Table 3.

[ Table 3]

^aMeasurement by Using the precipitated crude product of Compound (IV) obtained in example 2

^bMeasurement was carried out by using compound (IV) obtained by the production method described in patent document 1 (example 368)

^cMeasurement was performed by using precipitated crude products of the compound (IV) obtained by the production methods described in patent document 2 (refer to example 3), patent document 3 (example 4), patent document 4 (production example 3), and patent document 5 (example 1a)

The calculation of area% in table 3 was performed as follows. The peak area of the peak in the chromatogram derived from the sample obtained under the following measurement conditions was calculated, the peak area of each peak was divided by the total area to take the sum of the peak patterns corresponding to the impurities as the total content of the impurities and the pattern corresponding to the compound (IV) as the content of the compound (IV).

In addition, the calculation of% by mass in table 3 was performed as follows. First, as for the content of the compound (IV), the content of the compound (IV) in the sample is calculated by using a standard of the compound (IV) obtained by crystallization as an external control and comparing peak areas each corresponding to a peak of the compound (IV) in the standard and in the sample. Subsequently, in order to compensate for the difference in the absorbance per unit mass of each impurity, after each impurity was identified according to the procedure described in purity test 2 and a sample of each impurity was synthesized, the absorbance (sensitivity is a number) of each impurity was determined when the absorbance of compound (IV) was set to 1. Then, the mass (%) of each impurity was calculated by using the peak area and sensitivity of the impurity in the sample as numbers, and the total amount of the impurity detected to exceed 0.05% by mass was taken as the total content of the impurity.

Conditions for liquid chromatography measurement

A detector: ultraviolet absorptiometer (measuring wavelength: 252 nm).

Column: YMC-Pack ProC18(YMC Inc. (vimei instruments)), inner diameter: 4.6mm, length: 15cm, filler particle size: 3 μm

Column temperature: the constant temperature is close to 25 DEG C

Mobile phase: as shown in table 2, solution a and solution B having the following compositions were eluted with a linear gradient.

Solution A: water/acetonitrile/70% perchloric acid mixture (990:10:1, v/v/v)

Solution B: water/acetonitrile/70% perchloric acid mixture (100:900:1, v/v/v)

Flow rate: 1.0mL/min

Injection rate: 10 μ L

Temperature of the sample holder: the constant temperature is close to 15 DEG C

Area measurement range: 45 minutes

[ Table 4]

Time (min)	Proportion of solution B in the mobile phase (vol%)
		0	15
35	40
		42	100
45	100
		45.01	15
55	Stop

It should be noted that the limit of quantitation (lower limit) of the compound (A-1), the compound (I), and the compound (C-1) under the measurement conditions of the purity test 1 is 0.0020% by mass (20 ppm by mass), and 0.0022% by mass (22 ppm by mass), respectively.

Purity test 2

Under the measurement conditions of purity test 1, the retention times of each of compound (A-1), compound (I), compound (C-1), and compound (IV) were compared. The "relative retention time" shown in Table 5 refers to the relative retention time of compound (A-1), compound (I), and compound (C-1) with respect to compound (IV). That is, a value obtained by dividing the retention time of a peak on a chromatogram obtained under the measurement conditions of purity test 1 derived from each compound by the retention time of a peak obtained by injecting compound (IV) is the "relative retention time" as described.

[ Table 5]

Compound (I)	Relative retention time
		Compound (I)	0.74
Compound (A-1)	0.26
		Compound (C-1)	1.86

Under the measurement conditions described above, the individual compounds were identified on the basis of the following facts: the elution time of the compound in HPLC corresponds to the elution time of the sample. It should be noted that samples of each compound were synthesized separately and based on them¹H-NMR and MS spectra each determine its chemical structure.

Compound (C-1):1- { 2-chloro-4- [ (6-cyano-7-methoxy-quinolin-4-yl) oxy]Phenyl } -3-cyclopropyl Urea

¹H-NMR(600MHz,DMSO-d₆)δ(ppm):0.42(2H,m),0.66(2H,m),2.57(1H,dtt,J＝3,4,7Hz),4.05(3H,s),6.58(1H,d,J＝5Hz),7.20(1H,d,J＝3Hz),7.25(1H,dd,J＝3,9Hz),7.49(1H,d,J＝3Hz),7.58(1H,s),7.98(1H,s),8.28(1H,d,J＝9Hz),8.72(1H,s),8.73(1H,d,J＝5Hz)。

Subsequently, with respect to the compound (IV) obtained in example 2 and the compounds (IV) obtained by patent documents 2, 3, 4, and 5, the content of the compound (a-1) was measured by liquid chromatography. As a result, as shown in table 6, the content of the compound (a-1) in the compound (IV) obtained by the production methods described in patent documents 2, 3, 4, and 5 was 1311ppm by mass, while the content in the compound (IV) obtained in example 2 was reduced to 20ppm by mass or less.

[ Table 6]

^*The respective measurements were carried out by using the precipitated crude product from the reaction solution

^**Production methods described in patent document 2 (refer to example 3), patent document 3 (example 4), patent document 4 (production example 3), and patent document 5 (example 1a)

With respect to the compound (IV) obtained in example 2 and the compound (IV) obtained by the production method described in patent document 1, the content of the compound (C-1) was measured by liquid chromatography. As a result, as shown in table 7, the content of the compound (C-1) in the compound (IV) obtained by the production method described in patent document 1 was 3.37% by mass, while the content of the compound (C-1) in the compound (IV) obtained in example 2 was reduced to 0.05% by mass or less.

[ Table 7]

^*Measurement by Using the precipitated crude product of Compound (IV) obtained in example 2

^**Measurement was carried out by using compound (IV) obtained by the production method described in patent document 1 (example 368)

Purity test 3

With respect to the methanesulfonate salt of compound (IV) obtained in example 3, compound (C-1) under the following measurement condition A and compound (A-1) and compound (I) under the following measurement condition B were each detected. Specifically, for compound (a-1) and compound (I), measurement can be performed with good sensitivity by an external standard method in which a standard solution prepared from a standard is used under the following conditions. Note that the purity of the methanesulfonate salt of the compound (IV) obtained in example 3 was 99.3% by mass.

Conditions for liquid chromatography measurement

A detector: ultraviolet absorptiometer (measuring wavelength: 252 nm).

Column: YMC-Pack ProC18(YMC Inc. (vimei instruments)), inner diameter: 4.6mm, length: 7.5cm, filler particle size: 3 μm

Column temperature: the constant temperature is close to 40 DEG C

Mobile phase: as shown in table 8, solution a and solution B having the following compositions were eluted with a linear gradient.

Solution A: water/acetonitrile/70% perchloric acid mixture (990:10:1, v/v/v)

Solution B: water/acetonitrile/70% perchloric acid mixture (100:900:1, v/v/v)

Flow rate: 1.0mL/min

Injection rate: 10 μ L

Temperature of the sample holder: the constant temperature is close to 15 DEG C

Area measurement range: 30 minutes

[ Table 8]

It should be noted that under the above measurement condition A in the purity test 3, the limit of quantitation (lower limit) of the compound (C-1) is 0.01% by mass.

Conditions for liquid chromatography measurement

A detector: ultraviolet absorptiometer (measuring wavelength: 252 nm).

Column: YMC-Pack ProC18(YMC Inc. (vimei instruments)), inner diameter: 4.6mm, length: 7.5cm, filler particle size: 3 μm

Column temperature: the constant temperature is close to 40 DEG C

Mobile phase: as shown in table 9, solution a and solution B having the following compositions were eluted with a linear gradient.

Solution A: water/acetonitrile/70% perchloric acid mixture (990:10:1, v/v/v)

Solution B: water/acetonitrile/70% perchloric acid mixture (100:900:1, v/v/v)

Flow rate: 1.0mL/min

Injection rate: 5 μ L

Temperature of the sample holder: the constant temperature is close to 15 DEG C

Area measurement range: 13 minutes

[ Table 9]

It should be noted that the limit of quantitation (lower limit) of the compound (I) and the compound (A-1) under the measurement condition B is 7ppm by mass and 12ppm by mass, respectively.

The contents of the respective compounds obtained are shown in Table 10.

[ Table 10]

Impurities	Content (wt.)
		Compound (I)	52ppm by mass
Compound (A-1)	12ppm or less by mass
		Compound (C-1)	Less than or equal to 0.05 percent by mass

Example 6

Capsules of 4-mg capsules and 10-mg capsules were produced by using the methanesulfonate of compound (IV) shown in table 1 or table 2 and using D-mannitol, precipitated calcium carbonate, low-substituted hydroxypropylcellulose, crystalline cellulose, hydroxypropylcellulose, talc, and the like. It should be noted that "4-mg capsule" refers to a capsule containing 4mg of compound (IV) within the capsule. The mass of the granules, i.e. the content of capsules, was 100mg per capsule. In producing the capsules, the content (% by mass) (also referred to as "initial content") of the compound (I) relative to the total mass of the capsules is shown in table 11.

[ Table 11]

Accelerated tests (40 ℃/75% RH, PTP (molding material: aluminum composite film (polyamide/aluminum/polyvinyl chloride), lid material: aluminum foil)) and long-term storage tests (25 ℃/60% RH, PTP (molding material: aluminum composite film (polyamide/aluminum/polyvinyl chloride), lid material: aluminum foil)) were carried out by using 4-mg and 10-mg capsules of the compound (IV) produced in 5, 6, or 7 batches using methanesulfonic acid of the compound (IV) (mass of the granules, i.e., content of the capsules, 100mg per capsule).

In the accelerated tests for 4-mg and 10-mg capsules, the content of compound (I) was increased by up to 0.02% by mass and 0.01% by mass, respectively, compared to the initial content. In addition, the content of compound (I) was slightly increased in the long-term storage test for 24 months compared to the initial content. The increase in the content of compound (I) in the long-term storage test is less than the effective figure of the limit of quantitation, and specifically 0.003% by mass to 0.004% by mass. The measurement of the content of compound (I) in these capsules was performed by liquid chromatography (detection limit (lower limit): 0.0020% by mass), and the quantification limit (lower limit) was 0.01% by mass.